(CDXS) Codexis - Ratings and Ratios

Codexis Inc. is a leader in enzyme engineering and biocatalyst development, leveraging its proprietary CodeEvolver platform to enhance chemical transformations. This platform accelerates the discovery and optimization of enzymes for various industries, including pharmaceuticals, food, and flavor. The company offers a range of biocatalyst products and services, complemented by advanced screening and engineering solutions.

Codexis is advancing its ECO Synthesis manufacturing platform to revolutionize the production of RNAi therapeutics through enzymatic processes, addressing critical industry challenges. In collaboration with Nestlé Health Science, they are developing CDX-7108 to treat exocrine pancreatic insufficiency, highlighting their focus on gastrointestinal health. Their business model integrates direct sales and strategic partnerships, serving clients in the U.S. and Europe since 2002 from their Redwood City, California headquarters.

From a technical standpoint, Codexis stock (NASDAQ:CDXS) is currently trading at $3.04 with an average 20-day volume of 650,714 shares. The stock is below its 20 and 50-day moving averages of $4.16 and $4.62, respectively, but above the 200-day SMA of $3.72. The ATR of 0.30 indicates moderate volatility.

Fundamentally, Codexis has a market cap of $319.82 million. The forward P/E ratio of 138.89 reflects high growth expectations, though the current P/E is 0, suggesting ongoing investments in growth over profitability. The P/B ratio of 4.61 and P/S of 4.96 indicate a premium valuation relative to book value and revenue. The negative RoE of -84.59% highlights current profitability challenges.

Over the next three months, Codexis stock is expected to face headwinds due to its position below key moving averages, potentially leading to sideways movement or a slight decline. However, positive news on partnerships or platform advancements could counterbalance this trend, driven by the markets anticipation of growth indicated by the high forward P/E ratio.